What is he best known for?
The fields of study he is best known for:
His scientific interests lie mostly in DNA repair, Molecular biology, Fanconi anemia, Fanconi anemia, complementation group C and FANCD2.
His DNA repair research is multidisciplinary, relying on both DNA damage and Genome instability.
His Molecular biology research incorporates elements of Cell culture, Complementary DNA, Chromatin, Erythropoietin receptor and Phosphorylation.
His Fanconi anemia study combines topics from a wide range of disciplines, such as Cancer research, Disease, BRIP1, Cell cycle and Chromosome instability.
His work deals with themes such as FANCG, FAN1 and FANCB, which intersect with Fanconi anemia, complementation group C.
His studies deal with areas such as Ataxia-telangiectasia and Ubiquitin ligase as well as FANCD2.
His most cited work include:
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2498 citations)
- Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. (1081 citations)
- Biallelic Inactivation of BRCA2 in Fanconi Anemia (1011 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Cancer research, Molecular biology, Fanconi anemia, DNA repair and Internal medicine.
His Cancer research research focuses on subjects like PARP inhibitor, which are linked to Olaparib.
His work focuses on many connections between Molecular biology and other disciplines, such as Erythropoietin receptor, that overlap with his field of interest in Cell culture and SOCS2.
His Fanconi anemia research is included under the broader classification of Genetics.
His work carried out in the field of DNA repair brings together such families of science as Homologous recombination, DNA damage, Genome instability and Cell biology.
His FANCD2 study incorporates themes from FANCM and Monoubiquitination.
He most often published in these fields:
- Cancer research (37.08%)
- Molecular biology (34.52%)
- Fanconi anemia (30.77%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (37.08%)
- Homologous recombination (10.85%)
- PARP inhibitor (7.69%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Cancer research, Homologous recombination, PARP inhibitor, Cancer and DNA repair.
His Cancer research research is multidisciplinary, relying on both DNA damage, Genome instability, Poly ADP ribose polymerase, Gene and Ovarian cancer.
His research integrates issues of Synthetic lethality, Polymerase, Fanconi anemia and CRISPR in his study of Homologous recombination.
Alan D. D'Andrea interconnects Progenitor cell, Haematopoiesis and Cell biology in the investigation of issues within Fanconi anemia.
Alan D. D'Andrea has included themes like RNA interference, Microsatellite instability and DNA replication in his DNA repair study.
His DNA study combines topics in areas such as Molecular biology and Gene knockdown.
Between 2017 and 2021, his most popular works were:
- Mechanisms of PARP inhibitor sensitivity and resistance (116 citations)
- Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids (108 citations)
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma (105 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
